SYNAPTOGENIX INC (SNPX) Stock Price, Forecast & Analysis
USA - NASDAQ:SNPX - US87167T3005 - Common Stock
SNPX Key Statistics, Chart & Performance
The current stock price of SNPX is 7.85 USD. In the past month the price increased by 212.13%. In the past year, price increased by 91%.
SNPX Latest News, Press Relases and Analysis
SNPX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.85 | 381.38B | ||
| AMGN | AMGEN INC | 13.6 | 159.73B | ||
| GILD | GILEAD SCIENCES INC | 15.02 | 152.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.29 | 108.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.95 | 66.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 830.33 | 55.51B | ||
| ARGX | ARGENX SE - ADR | 62 | 51.19B | ||
| INSM | INSMED INC | N/A | 38.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.99 | 33.96B | ||
| NTRA | NATERA INC | N/A | 26.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
| BIIB | BIOGEN INC | 8.92 | 21.89B |
Related stock screener links
About SNPX
Company Profile
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The firm is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Company Info
SYNAPTOGENIX INC
1185 Avenue Of The Americas, 3Rd Floor
New York City NEW YORK US
CEO: Alan J. Tuchman
Employees: 5
Phone: 19732420005
SYNAPTOGENIX INC / SNPX FAQ
What does SYNAPTOGENIX INC do?
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The firm is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
What is the current price of SNPX stock?
The current stock price of SNPX is 7.85 USD. The price increased by 29.86% in the last trading session.
Does SNPX stock pay dividends?
SNPX does not pay a dividend.
How is the ChartMill rating for SYNAPTOGENIX INC?
SNPX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists SNPX stock?
SNPX stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for SNPX stock?
SYNAPTOGENIX INC (SNPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.81).
SNPX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SNPX. When comparing the yearly performance of all stocks, SNPX is one of the better performing stocks in the market, outperforming 98.59% of all stocks.
SNPX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNPX. SNPX has a great financial health rating, but its profitability evaluates not so good.
SNPX Financial Highlights
Over the last trailing twelve months SNPX reported a non-GAAP Earnings per Share(EPS) of -9.81. The EPS increased by 73.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.58% | ||
| ROE | -201.09% | ||
| Debt/Equity | 0 |
SNPX Forecast & Estimates
7 analysts have analysed SNPX and the average price target is 14.28 USD. This implies a price increase of 81.91% is expected in the next year compared to the current price of 7.85.